Core Insights - HEALWELL AI Inc. reported record revenue of approximately $103.8 million for fiscal 2025, marking a 427% increase from $19.7 million in fiscal 2024, and achieved its first full year of positive Adjusted EBITDA of $2.3 million [4][5] Financial Performance - The company experienced a significant financial transformation, swinging from a $14.2 million Adjusted EBITDA loss in 2024 to a $2.3 million positive Adjusted EBITDA in 2025, reflecting a $16.5 million improvement [2][4] - HEALWELL ended 2025 with $18.6 million in cash, compared to $9.4 million at the end of 2024, indicating an improving balance sheet [4][5] - The company reported an IFRS net loss from continuing operations of $39.1 million in 2025, compared to a net loss of $24 million in 2024 [5] Operational Highlights - HEALWELL transitioned to a pure-play AI and software company, completing strategic divestments that generated approximately $9.7 million in cash proceeds [4][5] - The company achieved a gross profit of $57.3 million in 2025, with a gross margin percentage of 55%, consistent with the previous year [5] - In Q4 2025, HEALWELL reported quarterly revenue of $32.2 million, a 374% increase from $6.8 million in Q4 2024, and positive Adjusted EBITDA of $1.1 million [5][9] Strategic Initiatives - HEALWELL has established a competitive position with 47 peer-reviewed publications supporting its DARWEN AI engine and over 70 enterprise customers across 11 countries [2][4] - The company is focusing on global scaling, deepening AI adoption, and translating platform economics into sustained profitability in 2026 [2][4] - HEALWELL launched WELLTRUST™, a consent-first patient identification platform, and announced a multi-million dollar U.S. Health Information Exchange (HIE) contract, expanding its enterprise data interoperability footprint [9]

Core Insights - HEALWELL AI Inc. has announced continued scientific validation of its DARWEN™ AI platform, with new research accepted for presentation at major international conferences, indicating significant commercial opportunities with existing pharmaceutical customers [1][10] Group 1: Scientific Validation and Research - The total number of peer-reviewed publications validating DARWEN™ AI has reached 47, covering multiple disease areas and diverse patient populations [2][10] - In 2026, HEALWELL has secured three additional conference acceptances in collaboration with leading global life sciences companies, showcasing the growing adoption of DARWEN™ AI in clinical research [2][10] - The studies demonstrate DARWEN™ AI's capability to generate clinical insights from large-scale real-world healthcare data, supporting research and quality improvement initiatives [2][8] Group 2: Strategic Partnerships and Market Impact - HEALWELL's strategy focuses on activating healthcare system data using its clinically validated DARWEN™ AI engine while expanding distribution through partnerships with healthcare providers and life sciences companies [5][9] - Each new publication enhances DARWEN™ AI's scientific credibility and expands its validation across additional disease states, facilitating informed decisions by healthcare organizations [5][9] - The growing body of evidence establishes a defensible foundation for broader adoption across healthcare systems and pharmaceutical research [5][8] Group 3: Technological Capabilities - DARWEN™ AI is designed to unlock insights from unstructured clinical data within electronic health records, transforming it into structured, research-ready insights [4][6] - The platform has demonstrated the ability to analyze millions of clinical records while maintaining research-grade rigor, reinforcing its credibility within the global academic and life sciences research community [6][8] - Research validating DARWEN™ AI spans a broad range of therapeutic areas, enhancing its applicability for population health management and precision medicine initiatives [7][12]

Core Insights - HEALWELL AI Inc. has announced the global launch of AmadeusAI, which integrates with its DARWEN™ AI technology to enhance healthcare providers' capabilities in patient identification and data analysis [2][3] - The AmadeusAI platform is designed to improve clinical workflows by transforming clinical data into actionable insights, thereby enabling faster identification of at-risk patients and better population health management [2][3][4] Company Update - The integration of Orion Health's Amadeus platform with HEALWELL's AI technology marks a significant milestone, allowing healthcare providers to gain deeper insights from both structured and unstructured clinical data [2][3] - AmadeusAI is now available as an upgrade for existing Amadeus customers, highlighting the strategic benefits of the Orion Health acquisition [3][6] Product Features - AmadeusAI includes the SMARTSuite of AI tools, which consists of SMARTSearch, SMARTSummary, and SMARTIdentify, aimed at streamlining clinical workflows and enhancing patient care [3][4] - SMARTSearch allows clinicians to retrieve information using natural language across various records, while SMARTSummary synthesizes fragmented patient data into concise narratives [4] - SMARTIdentify focuses on proactive patient cohort identification and risk stratification, shifting care from reactive to preventive [4] Market Position - HEALWELL's AmadeusAI has been deployed in various healthcare systems globally, including the NHS in the UK and health networks in Canada, New Zealand, and Australia, serving over 150 million patients [5][6] - The company is actively engaging with health systems to explore proof-of-value opportunities for its AI components, aiming to demonstrate the efficiency and outcome improvements enabled by integrated AI [6]